Clinical Trials Logo

Clinical Trial Summary

This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.


Clinical Trial Description

This is an international, open-label, controlled two-arm, randomised phase III study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC. The analysis will be done after 331 events are reported. In order to observe this number of events, 490 patients will be randomised (1:1) to receive trifluridine/tipiracil in combination with bevacizumab (experimental arm) or trifluridine/tipiracil monotherapy (control arm). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04737187
Study type Interventional
Source Taiho Oncology, Inc.
Contact
Status Completed
Phase Phase 3
Start date November 25, 2020
Completion date September 12, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04527068 - QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer Phase 2
Recruiting NCT05248048 - NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer Early Phase 1
Active, not recruiting NCT05205330 - A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients Phase 1/Phase 2
Active, not recruiting NCT05733611 - RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC Phase 2
Recruiting NCT05991102 - Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer N/A
Recruiting NCT05213195 - NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Phase 1
Completed NCT02860546 - A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC Phase 2